OncLive TV

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis. 

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.

Heinz-Josef Lenz, MD, FACP, discusses optimal sequencing strategies for the treatment of patients with colorectal cancer.

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer. 

Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

Shuo Ma, MD, PhD, highlights ongoing ​research with BTK inhibitor​s in B​-cell malignancies. 

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for ​evaluating lipophilic statins in epithelial ovarian cancer. 

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses recent advancements made in the field of triple-negative breast cancer.

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in ​uterine and soft tissue leiomyosarcoma. 

Rutika J. Mehta, MD, MPH, discusses the ​current treatment paradigm in HER2-positive gastric cancer. 

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.